CD274 and neoplasm: The phase 2 Lung Cancer Mutation Consortium 3 (LCMC3) trial showed that MPR was associated with baseline PD-L1 tumor proportion score (TPS) in NSCLC patients treated with atezolizumab monotherapy; a considerably higher pathological response was observed in patients with TPS ≥ 50% compared with those with TPS < 50% (27, 28).